New Charter Seeks to Build Global Support for Tolerance and Religious Freedom
10.12.2019 16:13:00 EET | Business Wire | Press release
This week some of the world’s most respected Islamic scholars, joined by experts from governments, civil society groups and other faiths, will launch a new effort to build global peace, based on tolerance and religious freedom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005594/en/
New Charter Seeks to Build Global Support for Tolerance and Religious Freedom (Photo: AETOSWire)
At the sixth Assembly of the Forum for Promoting Peace in Muslim Societies, in Abu Dhabi, Shaykh Abdullah bin Bayyah, President of the Forum, will inaugurate the charter of the “New Alliance of Virtue”. Its text will be revealed and signed by its first signatories.
The charter aims to elevate religious freedom, cooperation, and tolerance from mere possibilities to necessary ethical commitments and legal obligations, especially in relation to the protection of places of worship whose attacks have threatened freedom of religion in many parts of the world.
This initiative draws direct inspiration from the earliest traditions of Islam.
The original Alliance of Virtue (hilf al-fudul) was established in early 7th century AD (late 1st century BH) Mecca, in the house of Abdullah ibn Judan.
Its purpose was to defend the weak and the innocent against the rapaciousness of those more powerful.
The Prophet of Islam, Mohammad, and the first of the Rightly Guided Caliphs, Abu Bakr, were both present when the Alliance was formed, though it was before Mohammad’s prophethood. He later praised it, saying: “I was present in the house of Ibn Judan when an alliance was formed, and were I to have been called upon by it in Islam, I would have answered its call.”
Last February in Washington D.C., H.E. Shaykh Abdullah bin Bayyah, President of the Forum for Promoting Peace, led a panel of over 200 individuals from the three Abrahamic faiths and others, comprising religious leaders and senior politicians in creating the modern Alliance of Virtue between religions.
The charter of the New Alliance of Virtue follows the model of the original, on a global scale. It brings together those of good-will for the benefit of humanity, an effort across religions to enable its members to live side-by-side in peace and happiness.
The charter doesn’t aim to bridge theological differences, members will instead cooperate based on a common theology of God-given human dignity, seeking virtue for the benefit of all.
Notes for Editors
The Forum for Promoting Peace in Muslim Societies is led by Shaykh Abdullah bin Bayyah, under the patronage of His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister for Foreign Affairs and International Cooperation. The Forum mines the best global Islamic scholarly expertise for solutions to the challenge of securing global peace. The Forum seeks to extinguish the fire of extremism that has spread throughout the world, with violence driven by erroneous and ill-informed interpretations of Islam. Participants will discuss and devise ways to challenge the extremism and politicisation which causes immense division and suffering.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005594/en/
Contact information
Forum for Promoting Peace in Muslim Societies
Zeshan Zafar, Executive Director, zeshan@peacems.com.
http://www.peacems.com/en/default.aspx
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom